fda compounding semaglutide enforcement 2025 news Compound versions of GLP-1 drugs for weight loss halted by Compounded Semaglutide: Safety & Regulation

Frequently Asked Questions What is the typical maximum dose of semaglutide used for weight loss treatment

Brand claims regarding effectiveness, mechanism, and manufacturing are attributed to the brand and are not independently verified

In phase 2 trial data published in The New England Journal of Medicine (2023), retatrutide demonstrated substantial weight loss in adults with obesity with some participants losing over 20% of their body weight over approximately 48 weeks

Results: nejm.org/doi/full/10.10 #ADA2023 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 trial results demonstrating 25% weight loss in half of people with #obesity